메뉴 건너뛰기




Volumn 28, Issue 6, 2012, Pages 1053-1058

Comparability and biosimilarity: Considerations for the healthcare provider

Author keywords

Biologic; Biosimilar; Biosimilarity; Comparability; Innovator; Manufacturing

Indexed keywords

CELL CULTURE; CELL LINE; HEALTH CARE PERSONNEL; KNOWLEDGE; PRODUCT DEVELOPMENT; PURIFICATION; REVIEW;

EID: 84862581676     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.686902     Document Type: Review
Times cited : (87)

References (29)
  • 2
    • 45149128290 scopus 로고    scopus 로고
    • Current perspectives on stability of protein drug products during formulation, fill and finish operations
    • Rathore N, Rajan RS. Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog 2008;24: 504-14.
    • (2008) Biotechnol Prog , vol.24 , pp. 504-514
    • Rathore, N.1    Rajan, R.S.2
  • 3
    • 33947660965 scopus 로고    scopus 로고
    • Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes
    • Sharma B. Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes. Biotechnol Adv 2007;25:325-31
    • (2007) Biotechnol Adv , vol.25 , pp. 325-331
    • Sharma, B.1
  • 4
    • 3042780397 scopus 로고    scopus 로고
    • Current and future considerations for the new classes of biologicals
    • Kleinberg M, Mosdell KW. Current and future considerations for the new classes of biologicals. Am J Health Syst Pharm 2004;61:695-708.
    • (2004) Am J Health Syst Pharm , vol.61 , pp. 695-708
    • Kleinberg, M.1    Mosdell, K.W.2
  • 5
    • 77950877204 scopus 로고    scopus 로고
    • Application of near-infrared (NIR) spec-troscopy for screening of raw materials used in the cell culture medium for the production of a recombinant therapeutic protein
    • Kirdar AO, Chen G, Weidner J, et al. Application of near-infrared (NIR) spec-troscopy for screening of raw materials used in the cell culture medium for the production of a recombinant therapeutic protein. Biotechnol Prog 2010;26:527-31
    • (2010) Biotechnol Prog , vol.26 , pp. 527-531
    • Kirdar, A.O.1    Chen, G.2    Weidner, J.3
  • 6
    • 79551563213 scopus 로고    scopus 로고
    • Comparability assessments of process and product changes made during development of two different monoclonal antibodies
    • Lubiniecki A, Volkin DB, Federici M, et al. Comparability assessments of process and product changes made during development of two different monoclonal antibodies. Biologicals 2011;39:9-22.
    • (2011) Biologicals , vol.39 , pp. 9-22
    • Lubiniecki, A.1    Volkin, D.B.2    Federici, M.3
  • 7
    • 34547637286 scopus 로고    scopus 로고
    • Combined approach of NMR and chemometrics for screening peptones used in the cell culture medium for the production of a recombinant therapeutic protein
    • Luo Y, Chen G. Combined approach of NMR and chemometrics for screening peptones used in the cell culture medium for the production of a recombinant therapeutic protein. Biotechnol Bioeng 2007;97:1654-9.
    • (2007) Biotechnol Bioeng , vol.97 , pp. 1654-1659
    • Luo, Y.1    Chen, G.2
  • 8
    • 77954937558 scopus 로고    scopus 로고
    • Summary of DIA Workshop: Comparability challenges: Regulatory and scientific issues in the assessment of biopharmaceu-ticals
    • Lewis RM, Cosenza ME. Summary of DIA Workshop: Comparability challenges: Regulatory and scientific issues in the assessment of biopharmaceu-ticals. Drug Inf J 2010;44:485-504.
    • (2010) Drug Inf J , vol.44 , pp. 485-504
    • Lewis, R.M.1    Cosenza, M.E.2
  • 9
    • 77956873702 scopus 로고    scopus 로고
    • Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies
    • Putnam WS, Prabhu S, Zheng Y, et al. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 2010;28:509-16.
    • (2010) Trends Biotechnol , vol.28 , pp. 509-516
    • Putnam, W.S.1    Prabhu, S.2    Zheng, Y.3
  • 10
    • 84862542513 scopus 로고    scopus 로고
    • Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER) [Last accessed 19 December 2011]
    • Demonstration of comparability of human biological products, including therapeutic biotechnology-derived products. Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER), 1996. Available at: http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm122879.htm [Last accessed 19 December 2011]
    • Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products , vol.1996
  • 11
    • 75649144138 scopus 로고    scopus 로고
    • Rockville, MD: FDA/Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER) [Last accessed 19 December 2011]
    • Q5E Comparability of biotechnological/biological products subject to changes in their manufacturing process. Rockville, MD: FDA/Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER), 2005. Available at: http://www.fda.gov/downloads/RegulatoryInformation/ Guidances/ucm128076.pdf [Last accessed 19 December 2011]
    • (2005) Q5E Comparability of Biotechnological/biological Products Subject to Changes in Their Manufacturing Process
  • 12
    • 84862541885 scopus 로고    scopus 로고
    • International Conference on Harmonization/ICH Expert Working Group [Last accessed 9 March 2012]
    • Comparability of biotechnological/biological products subject to changes in their manufacturing process, Q5E. International Conference on Harmonization/ICH Expert Working Group 2004. Available at: http://www.i-ch.org/ fileadmin/Public/Web/Site/ICH/Products/Guidelines/Quality/Q5E/Step4/Q5E/ Guideline.pdf [Last accessed 9 March 2012]
    • (2004) Comparability of Biotechnological/biological Products Subject to Changes in Their Manufacturing Process, Q5E
  • 13
    • 84862557851 scopus 로고    scopus 로고
    • Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER) [Last accessed 19 December 2011]
    • Avonexs Summary Basis for Approval. Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER), 2004. Available at: http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm086056.pdf [Last accessed 19 December 2011]
    • (2004) Avonex Summary Basis for Approval
  • 14
    • 84856542980 scopus 로고    scopus 로고
    • London: European Medicines Agency[Last accessed 16 March 2012]
    • Raptiva European Public Assessment Report Scientific Discussion. London: European Medicines Agency, 2004. Available at: http://www.ema.europa.eu/docs/en/ GB/document/library/EPAR/-/Scientific/Discussion/human/000542/WC500057849.pdf [Last accessed 16 March 2012]
    • (2004) Raptiva European Public Assessment Report Scientific Discussion
  • 16
    • 33644952525 scopus 로고    scopus 로고
    • London: European Medicines Agency [Last accessed 19 December 2011)
    • Guideline on similar biological medicinal products. London: European Medicines Agency 2005. Available at: http://www.emea.europa.eu/pdfs/human/ biosimilar/043704en.pdf [Last accessed 19 December 2011)
    • (2005) Guideline on Similar Biological Medicinal Products
  • 17
    • 34548168792 scopus 로고    scopus 로고
    • EMEA guidelines on biosimilars and their clinical implications
    • Rossert J. EMEA guidelines on biosimilars and their clinical implications. Kidney Blood Press Res 2007;30(Suppl1):13-17.
    • (2007) Kidney Blood Press Res , vol.30 , Issue.SUPPL. 1 , pp. 13-17
    • Rossert, J.1
  • 18
    • 84860314070 scopus 로고    scopus 로고
    • Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER) [Last accessed 6 March 2012]
    • Scientific Considerations in Demonstrating Biosimilarity to a Reference Protein Product; Draft Guidance; 9 February 2012. Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER), 2012. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf [Last accessed 6 March 2012]
    • (2012) Scientific Considerations in Demonstrating Biosimilarity to A Reference Protein Product; Draft Guidance; 9 February 2012
  • 19
    • 79955655456 scopus 로고    scopus 로고
    • Biosimilars 2.0: Guiding principles for a global 'patients first' standard
    • Miletich J, Eich G, Grampp G, et al. Biosimilars 2.0: Guiding principles for a global 'patients first' standard. MAbs 2011;3:318-25.
    • (2011) MAbs , vol.3 , pp. 318-325
    • Miletich, J.1    Eich, G.2    Grampp, G.3
  • 20
    • 69449095403 scopus 로고    scopus 로고
    • Biosimilar therapeutics-what do we need to consider?
    • Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus 2009;2:i27-36
    • (2009) NDT Plus , vol.2
    • Schellekens, H.1
  • 21
    • 84855436897 scopus 로고    scopus 로고
    • Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin- A (HX575) in non-dialysis patients with renal anemia: A multi-center, randomized, double-blind study
    • Haag-Weber M, Eckardt KU, Hörl WH, et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-a (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012;77:8-17.
    • (2012) Clin Nephrol , vol.77 , pp. 8-17
    • Haag-Weber, M.1    Eckardt, K.U.2    Hörl, W.H.3
  • 22
    • 79952749322 scopus 로고    scopus 로고
    • Biosimilar agents in oncology/haematology: From approval to practice
    • Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: From approval to practice. Eur J Haematol 2010;86:277-88.
    • (2010) Eur J Haematol , vol.86 , pp. 277-288
    • Niederwieser, D.1    Schmitz, S.2
  • 23
    • 52649084303 scopus 로고    scopus 로고
    • Recombinant human erythropoietins, biosimilars and immunogenicity
    • Schellekens H. Recombinant human erythropoietins, biosimilars and immunogenicity. J Nephrol 2008;21:497-502.
    • (2008) J Nephrol , vol.21 , pp. 497-502
    • Schellekens, H.1
  • 24
    • 67349221747 scopus 로고    scopus 로고
    • Assessing the bioequivalence of biosimilars: The Retacrit case
    • Schellekens H. Assessing the bioequivalence of biosimilars: The Retacrit case. Drug Discov Today 2009;14:495-9.
    • (2009) Drug Discov Today , vol.14 , pp. 495-499
    • Schellekens, H.1
  • 25
    • 84881443667 scopus 로고    scopus 로고
    • London: European Medicines Agency 2006 [Last accessed 16 March 2012]
    • Refusal assessment reportfor Alpheon. London: European Medicines Agency 2006. Available at: http://www.ema.europa.eu/docs/en/GB/document/li-brary/EPAR/- /Public/assessment/sreport/human/000585/WC500070792.pdf [Last accessed 16 March 2012]
    • Refusal Assessment Reportfor Alpheon
  • 26
    • 84946542353 scopus 로고    scopus 로고
    • London: European Medicines Agency [Last accessed 16 March 2012]
    • Withdrawal assessment for Insulin Human Rapid Marvel. London: European Medicines Agency, 2008. Available at: http://www.ema.europa.eu/docs/en/GB/ document/library/Application/withdrawal/assessment/report/2010/01/WC500067086. pdf [Last accessed 16 March 2012]
    • (2008) Withdrawal Assessment for Insulin Human Rapid Marvel
  • 27
    • 84946542353 scopus 로고    scopus 로고
    • London: European Medicines Agency[Last accessed 16 March 2012]
    • Withdrawal assessment for Insulin Human Long Marvel. London: European Medicines Agency, 2008. Available at: http://www.ema.europa.eu/docs/en/GB/ document/library/Application/withdrawal/assessment/report/2010/01/WC500067170. pdf[Last accessed 16 March 2012]
    • (2008) Withdrawal Assessment for Insulin Human Long Marvel
  • 28
    • 84862541886 scopus 로고    scopus 로고
    • London: European Medicines Agency 2008 [Last accessed 16 March 2012]
    • Withdrawal assessment for Insulin Human 30/70 Marvel. London: European Medicines Agency 2008. Available at: http://www.ema.europa.eu/docs/en/GB/ document/library/Application/withdrawal/assessment/report/2010/01/WC500067169. pdf [Last accessed 16 March 2012]
    • Withdrawal Assessment for Insulin Human 30/70 Marvel
  • 29
    • 84856808079 scopus 로고    scopus 로고
    • London: European Medicines Agency[Last accessed 16 March 2012]
    • Omnitrope® European Public Assessment Report Scientific Discussion. London: European Medicines Agency, 2006. Available at: http://www.ema. europa.eu/docs/en/GB/document/library/EPAR/-/Scientific/Discussion/human/000607/ WC500043692.pdf [Last accessed 16 March 2012]
    • (2006) Omnitrope European Public Assessment Report Scientific Discussion


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.